Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.
Highlights
The global Benign Prostatic Hyperplasia market was valued at US$ 11060 million in 2022 and is anticipated to reach US$ 14650 million by 2029, witnessing a CAGR of 4.8% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Benign Prostatic Hyperplasia is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Benign Prostatic Hyperplasia is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Benign Prostatic Hyperplasia in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Benign Prostatic Hyperplasia include Abbott, Allergan, Astellas Pharma, Boehringer Ingelheim Pharma, Eli Lilly and Company, GlaxoSmithKline, Merck, Pfizer and Sanofi, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia.
The Benign Prostatic Hyperplasia market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Benign Prostatic Hyperplasia market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi
Segment by Type
Drug Therapy
Dialysis
Others
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug Therapy
1.2.3 Dialysis
1.2.4 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Market Perspective (2018-2029)
2.2 Benign Prostatic Hyperplasia Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Benign Prostatic Hyperplasia Historic Market Size by Region (2018-2023)
2.2.3 Benign Prostatic Hyperplasia Forecasted Market Size by Region (2024-2029)
2.3 Benign Prostatic Hyperplasia Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Industry Trends
2.3.2 Benign Prostatic Hyperplasia Market Drivers
2.3.3 Benign Prostatic Hyperplasia Market Challenges
2.3.4 Benign Prostatic Hyperplasia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Players by Revenue (2018-2023)
3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2018-2023)
3.2 Global Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Revenue
3.4 Global Benign Prostatic Hyperplasia Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Revenue in 2022
3.5 Benign Prostatic Hyperplasia Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Historic Market Size by Type (2018-2023)
4.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Type (2024-2029)
5 Benign Prostatic Hyperplasia Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Historic Market Size by Application (2018-2023)
5.2 Global Benign Prostatic Hyperplasia Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Benign Prostatic Hyperplasia Market Size (2018-2029)
6.2 North America Benign Prostatic Hyperplasia Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Benign Prostatic Hyperplasia Market Size by Country (2018-2023)
6.4 North America Benign Prostatic Hyperplasia Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Market Size (2018-2029)
7.2 Europe Benign Prostatic Hyperplasia Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Benign Prostatic Hyperplasia Market Size by Country (2018-2023)
7.4 Europe Benign Prostatic Hyperplasia Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Market Size (2018-2029)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2018-2023)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Market Size (2018-2029)
9.2 Latin America Benign Prostatic Hyperplasia Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Benign Prostatic Hyperplasia Market Size by Country (2018-2023)
9.4 Latin America Benign Prostatic Hyperplasia Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Market Size (2018-2029)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2018-2023)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Benign Prostatic Hyperplasia Introduction
11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.1.5 Abbott Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Benign Prostatic Hyperplasia Introduction
11.2.4 Allergan Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.2.5 Allergan Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.3.5 Astellas Pharma Recent Development
11.4 Boehringer Ingelheim Pharma
11.4.1 Boehringer Ingelheim Pharma Company Detail
11.4.2 Boehringer Ingelheim Pharma Business Overview
11.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Introduction
11.4.4 Boehringer Ingelheim Pharma Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.4.5 Boehringer Ingelheim Pharma Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Introduction
11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.5.5 Eli Lilly and Company Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Introduction
11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.6.5 GlaxoSmithKline Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Benign Prostatic Hyperplasia Introduction
11.7.4 Merck Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Benign Prostatic Hyperplasia Introduction
11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Benign Prostatic Hyperplasia Introduction
11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Business (2018-2023)
11.9.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi
听
听
*If Applicable.
